NUVL
Price
$92.52
Change
+$2.10 (+2.32%)
Updated
Oct 17 closing price
Capitalization
6.67B
18 days until earnings call
PHVS
Price
$21.12
Change
-$0.74 (-3.39%)
Updated
Oct 17 closing price
Capitalization
1.36B
17 days until earnings call
Interact to see
Advertisement

NUVL vs PHVS

Header iconNUVL vs PHVS Comparison
Open Charts NUVL vs PHVSBanner chart's image
Nuvalent
Price$92.52
Change+$2.10 (+2.32%)
Volume$351.66K
Capitalization6.67B
Pharvaris
Price$21.12
Change-$0.74 (-3.39%)
Volume$246.62K
Capitalization1.36B
NUVL vs PHVS Comparison Chart in %
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PHVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NUVL vs. PHVS commentary
Oct 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NUVL is a Hold and PHVS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 19, 2025
Stock price -- (NUVL: $92.52 vs. PHVS: $21.12)
Brand notoriety: NUVL and PHVS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NUVL: 86% vs. PHVS: 125%
Market capitalization -- NUVL: $6.67B vs. PHVS: $1.36B
NUVL [@Biotechnology] is valued at $6.67B. PHVS’s [@Biotechnology] market capitalization is $1.36B. The market cap for tickers in the [@Biotechnology] industry ranges from $106.87B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NUVL’s FA Score shows that 0 FA rating(s) are green whilePHVS’s FA Score has 0 green FA rating(s).

  • NUVL’s FA Score: 0 green, 5 red.
  • PHVS’s FA Score: 0 green, 5 red.
According to our system of comparison, NUVL is a better buy in the long-term than PHVS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NUVL’s TA Score shows that 6 TA indicator(s) are bullish while PHVS’s TA Score has 5 bullish TA indicator(s).

  • NUVL’s TA Score: 6 bullish, 4 bearish.
  • PHVS’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, NUVL is a better buy in the short-term than PHVS.

Price Growth

NUVL (@Biotechnology) experienced а +5.02% price change this week, while PHVS (@Biotechnology) price change was -3.91% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.56%. For the same industry, the average monthly price growth was +15.88%, and the average quarterly price growth was +79.09%.

Reported Earning Dates

NUVL is expected to report earnings on Nov 06, 2025.

PHVS is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+1.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVL($6.67B) has a higher market cap than PHVS($1.36B). NUVL YTD gains are higher at: 18.191 vs. PHVS (10.172). PHVS has higher annual earnings (EBITDA): -165.21M vs. NUVL (-362.01M). NUVL has more cash in the bank: 1.01B vs. PHVS (200M). NUVL (0) and PHVS (0) have equivalent revenues.
NUVLPHVSNUVL / PHVS
Capitalization6.67B1.36B491%
EBITDA-362.01M-165.21M219%
Gain YTD18.19110.172179%
P/E RatioN/AN/A-
Revenue00-
Total Cash1.01B200M503%
Total DebtN/A634K-
TECHNICAL ANALYSIS
Technical Analysis
NUVLPHVS
RSI
ODDS (%)
Bearish Trend 3 days ago
82%
Bullish Trend 3 days ago
81%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
86%
Momentum
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
83%
MACD
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
87%
Advances
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 4 days ago
77%
Declines
ODDS (%)
Bearish Trend 13 days ago
78%
Bearish Trend 10 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
86%
Aroon
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PHVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SVTAX11.290.10
+0.89%
SEI Global Managed Volatility F (SIMT)
FMDRX33.770.20
+0.60%
Franklin Mutual Global Discovery R6
FCAOX13.900.04
+0.29%
Fidelity Advisor Climate Action M
WRHIX5.970.01
+0.17%
Macquarie High Income Fund Class C
MICIX10.38-0.01
-0.10%
Victory Trivalent Intl Fd-Core Eq I

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with XENE. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
+2.32%
XENE - NUVL
61%
Loosely correlated
-1.28%
RVMD - NUVL
60%
Loosely correlated
+8.90%
CGON - NUVL
59%
Loosely correlated
-0.93%
XNCR - NUVL
58%
Loosely correlated
-1.20%
VRDN - NUVL
58%
Loosely correlated
+5.22%
More

PHVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, PHVS has been loosely correlated with NUVL. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if PHVS jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHVS
1D Price
Change %
PHVS100%
-3.39%
NUVL - PHVS
36%
Loosely correlated
+2.32%
INKT - PHVS
34%
Loosely correlated
-3.05%
SNDX - PHVS
32%
Poorly correlated
-4.98%
MGTX - PHVS
32%
Poorly correlated
-4.67%
GBIO - PHVS
31%
Poorly correlated
-6.93%
More